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ABSTRACT
Members of the Flaviviridae family constitute a severe risk to human
health. Whilst effective drugs have been developed against the
hepacivirus HCV, no antiviral therapy is currently available for any
other viruses, including the flaviviruses dengue (DENV), West Nile
and Zika viruses. The RNA-dependent RNA polymerase (RdRp) is
responsible for viral replication and represents an excellent
therapeutic target with no homologue found in mammals. The
identification of compounds targeting the RdRp of other flaviviruses
is an active area of research. One of the main factors hampering
further developments in the field is the difficulty in obtaining high-
quality crystal information that could aid a structure-based drug
discovery approach. To address this, we have developed a convenient
and economical 96-well screening platform. We validated the screen
by successfully obtaining crystals of both native DENV serotype 2 and
3 RdRps under several conditions included in the screen. In addition,
we have obtained crystal structures of RdRp3 in complex with
a previously identified fragment using both soaking and co-
crystallization techniques. This work will streamline and accelerate
the generation of crystal structures of viral RdRps and provide the
community with a valuable tool to aid the development of structure-
based antiviral design.
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INTRODUCTION
Flaviviridae are a family of enveloped, positive single stranded
RNA viruses. The genus Flavivirus, of the Flaviviridae family,
counts over 70 different viruses (Fields et al., 2007; Kuno et al.,
1998), including Dengue virus (DENV), Japanese encephalitis
virus (JEV), tick-borne encephalitis virus (TBEV), West Nile virus
(WNV), yellow fever virus (YFV) and Zika virus (ZIKV). Most of
these viruses are arthropod-borne and can cause widespread
morbidity and mortality. For instance, infection with DENV,
which is estimated to affect 390 million people annually (Bhatt
et al., 2013), can lead to an ample range of clinical manifestations,
from mild fever to fatal dengue shock syndrome (Rajapakse, 2011),
while infection with ZIKV has recently been shown to be
responsible for the sudden surge in the number of cases of
microcephaly and neurological abnormalities in new-borns, and for
several cases of Guillain-Barré syndrome (Dyer, 2015; Oliveira
Melo et al., 2016). No antivirals are currently available and vaccines
are limited to YFV, JEV and TBEV. The vaccine currently licensed
for DENV (Dengvaxia, Senofi-Pasteur) only has limited efficacy
against some DENV serotypes, and concerns have been raised over
its administration to children and seronegative individuals (Aguiar
et al., 2016). In the absence of safe and effective vaccines, and given
the risk of emergence of new flaviviruses, as demonstrated by the
recent re-emergence of ZIKV, the development of antivirals against
this group of viruses becomes ever more important.
The flavivirus genome of ∼11 kb is translated into a single
polyprotein which is processed into three structural (envelope,
membrane and capsid) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5). NS5 is the largest andmost
conserved protein, with members of the flavivirus genus sharing
approximately 60–65% sequence similarity (Lim et al., 2015).
DENV NS5 (∼900 aa) is comprised of a methyltransferase
(MTase) domain (∼250 aa) at the N-terminus, mainly responsible for
RNA cap formation during viral replication (Egloff et al., 2002; Ray
et al., 2006), and an RNA-dependent RNA polymerase (RdRp)
domain at the C-terminus (∼600 aa). The RdRp is mostly known for
its role in virus replication (Selisko et al., 2014). It functions by
replicating the viral genomic +RNA into uncapped –RNA, leading to
the formation of a double-stranded RNA intermediate, and then using
the –RNA template to synthesize new +RNA copies of the viral
genome (Malet et al., 2008). In addition, the RdRp plays an important
role in escaping the host immune response by blocking IFN type I
signalling through binding the transcription factor STAT2 and
promoting its degradation (Ashour et al., 2009; Mazzon et al., 2009).
The overall structure of the RdRp domain consists of three main
subdomains known as the ‘fingers’, ‘palm’ and ‘thumb’ (Fig. 1A).
These subdomains are made up of seven conserved motifs (A to G)
important for RNA binding and replication (Sousa, 1996; Malet
et al., 2007; Yap et al., 2007). Motifs F and G are believed to interact
with the RNA template (Iglesias et al., 2011) and with nucleoside
triphosphates (NTP) (Sousa, 1996) for RNA elongation. It has been
proposed that DENV RdRp undergoes a conformational change
from a ‘closed’ initiation complex, bound to single-stranded RNA,
to an ‘open’ elongation complex, bound to double-stranded RNA.
Not surprisingly, sections of the flexible loops from motifs F
(residues 455–468) and G (residues 406–417) are disordered and
not observed in the apo-structures (Yap et al., 2007). Structures ofReceived 17 August 2018; Accepted 26 October 2018
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dengue RdRp have only been solved in the closed conformation
(Noble and Shi, 2012). Interestingly, in the ligand bound structure
(PDB ID: 3VWS; Noble et al., 2013) one region involved in ligand
binding near motif G has the whole motif present although the
overall structure is still in the closed conformation.
Being essential for viral replication and with no equivalent in
host cells, DENV RdRp represents an attractive target for drug
development. Also, given its structural and conformational
conservation among the various serotypes (Rawlinson et al.,
2006), the RdRp domain represents one of the most viable targets
for the development of direct-acting DENV antivirals. The clinical
use of inhibitors against the HBV, HCV and herpes virus
polymerase as well as the HIV reverse transcriptase, has validated
viral polymerases as therapeutic targets (De Clercq et al., 2006). At
present, the only clinically approved antiviral therapy targeting a
Flaviviridae RdRp is used for the treatment of HCV infections
(Bonaventura and Montecucco, 2016; Younossi et al., 2016). The
study of antivirals targeting DENV RdRp has led to the
identification of a few potential candidates, but further work is
needed to develop a viable drug (Noble et al., 2013, 2016;
Yokokawa et al., 2016). In order to further advance drug
development efforts against the RdRp of DENV and other
Flaviviridae, determining the structures of the RdRps for rational
drug design is of crucial importance.
To date, several RdRp structures of various members of
the Flaviviridae family have been determined either in the apo
state or in complex with inhibitors or fragments (Noble et al.,
2013, 2016). Apo structures of RdRp provide information
about structural similarities and differences within the family,
which has to be taken into consideration during the various phases
of the drug discovery process. In contrast, crystal structures of
RdRps in complex with small molecules or fragments provide
insights into inhibitor binding pockets for the development of new
antivirals.
The commercial screens currently available for crystallization
trials require extensive screening for crystals, which is time
consuming, cumbersome and expensive. No targeted
crystallization screen for viral RdRp proteins is currently
available. In order to address these limitations, we have developed
a fast and cost-effective RdRp screen with the intent of facilitating
crystallization of RdRps from different viruses either alone, or in
complex with inhibitors or fragments. Our aim was to rationalize the
crystallization processes for different RdRps, by searching the PDB
and the literature for crystallization conditions of all known RdRp
structures, and to develop a screen specifically designed for
crystallization of these proteins. We devised a crystallization
screen comprising of 96 different conditions, optimized for use in
96-well plate format. We have further verified these screening
conditions by crystallizing the RdRps of DENV serotypes 2 and
3. Furthermore, we obtained RdRp3 in complex with the fragment
PC-79-SH52 (Noble et al., 2016) using our novel screen under both
soaking and co-crystallization conditions.
Fig. 1. Representative details of optimized cryo-conditions. The structure of dengue RdRp and the location of PEG-ions in the structure. (A) The overall
structure of the RdRp domain of dengue virus serotype 3. The different secondary elements represent the thumb (turquoise), finger (magenta), palm (purple)
and NLS regions (green). The two Zinc atoms are represented as blue spheres. (B) Representative diffraction pattern of RdRp crystals in the presence of
either 12% glycerol or 14% glycerol as a cryoprotectant are shown. 12% glycerol shows ice rings correlated with a decrease in resolution, which prompted us
to investigate 14% glycerol as a cryoprotectant (n=10, mean±s.d.). (C) Bar diagram of quantitative representation of number of datasets obtained with 12
(n=39) and 14% (n=41) glycerol as cryoprotectant that either had ice rings (black) or no ice rings (blue). (D) The PEG ions coordination and their electron
density omit map (coloured in grey) contoured at 1 σ. The numbering of PEG is based on the number of PEG molecules present in different structures. For
example, a structure with four PEG ions will contain PEG-1 to PEG-4. Figures B and C were prepared using PyMOL (Schrodinger, 2015).
(E) Various PEG molecules are located at the surface of RdRp and mediate interactions with symmetry-related molecules.
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RESULTS
Data mining and analysis of the PDB
Information about each viral RdRp was retrieved. This included the
PDB ID, crystallization method, pH, the crystal growth procedure
and conditions, the resolution, and space group for each entry. A
crystallization dataset with 201 unique entries was created as shown
in Table S1. The RdRp domains deposited in the PDB database
originate from 19 different viruses. The most studied virus is HCV,
counting 49% of all entries, reflecting the importance of HCVRdRp
as therapeutic target of new drugs introduced to the market,
followed at a significant distance by Poliovirus (12% of the entries).
Other extensively studied viruses are DENV serotype 3, foot and
mouth disease virus, and murine norovirus, each representing 5% of
the entries (Fig. 2A). The success of specific inhibitors against HCV
RdRp underpins the importance of this novel screen for structure-
based drug design targeting the RdRp of other viruses of significant
public health concern.
To generate the data set, analysis of the crystallization conditions
was carried out taking into account the precipitant used, the buffer,
as well as its pH, the salt composition and the crystallization
temperature (Table S1). Unfortunately, in about 15% of entries, the
information deposited in the PDB or in the corresponding
manuscript did not include exact crystallization conditions.
A range of temperatures from 273K (0°C) to 303K (30°C) were
used to crystallize RdRps. The most used temperatures were 293K
(20°C; 28%), 289K (16°C; 24%) and 298K (25°C; 16%). Only very
few structures were determined at 277K (4°C) (1%) and above 298K
(30°C) (0.5%). For 12% of entries there was no specified
crystallization temperature (Fig. 2B).
We observed that themajority of crystals were obtained in a range of
pH values between 4.6 and 10.0. Most of the structures were
determined at a pH between 7.0–7.5 (29%), and between 4.7–5.0
(28%), followed by pH ranges 6.0–6.6 (25%). The most used single
pH values were 7.5 (15%), 7.0 (13%), 4.9 (11.5%) and 5.0 (11%). For
6% of the entries there was no specified pH value (Fig. 2C).
The buffers used to maintain this pH principally included acetate
buffer (42%), tris (hydroxymethyl)amino-methane (Tris, 27%), citrate
(26%), cacodylate (16%), 2-[4-(2-hydroxyethyl) piperazine-1-yl]
ethane-sulfonic acid (HEPES, 14%), 2-(N-morpholino)
ethanesulfonic acid (MES, 14%), and Bis-tris propane buffer (11%).
Around 3% of entries did not specify the buffer used (Fig. 2D).
The precipitating agent most commonly employed for
crystallization was polyethylene glycol (PEG), used in 88% of the
cases. Avariety of PEGs with different molecular weights were used
including PEG 4000 (47%), followed by PEG 550 monomethyl
ether (MME, 16%), PEG 8000 and PEG 3350 (both 9%), PEG 400
(7%) and PEG 5000 MME (4%). The second most employed
precipitating agent were sulfate salts, in around 23% of the entries,
including ammonium sulfate in 9% of the cases, lithium sulfate
(11%) and magnesium sulfate (3%) (Fig. 2E).
Fig. 2. Analysis of PDB data. (A) Deposited structures of RdRp domains of different viruses. HCV has the highest number of PDB entries (∼100 structures),
whereas other major viruses have about 10–20 PDB entries. (B) A range of temperatures have been employed to obtain crystals for RdRp domains
with 20°C being the most common one followed by 16°C and room temperature (25°C). Other temperatures have been used sparingly to obtain crystals.
(C) Although a wide range of pH values have been successful in obtaining various crystals, pHs closer to physiological pH values have been more
successful than others. Bar diagram representation of percentage structures obtained (D) under various buffers and (E) obtained with various precipitating
agents from the PDB data analysis.
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Cations and additives also seemed to be important for the
formation of crystals. The most used monovalent cation is Na+ (51%)
from acetate buffer, sodium chloride and Na/K tartrate, followed at
some distance by Li+ (6%) (e.g. lithium sulfate and lithium nitrate)
and by K+ (3%) included in Na/K tartrate, potassium fluoride and
potassium phosphate. Divalent cations commonly used are Mg2+
(12%) such as magnesium chloride, acetate buffer and magnesium
sulfate, and Mn2+ (9%) from manganese chloride. Less used is Ca2+
(3%) such as in acetate buffer and calcium chloride.
In the case of additives, glycerol was used in 44% of all
crystallization conditions, but was also employed as a supplement
during protein purifications. This indicates that glycerol was used as
an additive to increase protein solubility, to decrease the number of
nucleation centres and as a cryo-protectant. Other alcohols such as
2-propanol (6%), ethylene glycol (2%) and 1,6-hexanediol (1%) have
been used as additives in the crystallization of various different RdRps.
Design of the RNA polymerase screen
Based on the most successful conditions identified in the PDB
analysis, the RNA polymerase screen was designed to include 96
crystallization conditions covering the widest possible variety of
precipitants, buffers and pH values, salts and additives. The identified
conditions were initially grouped based on the precipitant used and,
within each group, ordered by the precipitant concentration. Five
different precipitants were selected for the screen. Sparingly used
precipitants such as sodium potassium tartrate, ammonium sulfate,
etc. were employed to populate the majority of rows A and B of the
96-well screen format. According to the PDB analysis, different
concentrations (1–40%) of PEG chains of varying lengths (400–
20,000) were most abundantly used to obtain RdRp structures from
distinct viruses. Therefore, about 70 of the 96 formulated conditions
contain some form of PEG as a precipitant.
Next, we decided to include in the screen a pH distribution between
pH 4.7 and pH 10.0, in order to cover the pH range most frequently
used in the PDB dataset as extensively as possible. For each individual
precipitating agent, we moved from the lowest pH to the highest pH.
This trend has been maintained in a serpentine manner with the
majority of low pH values towards the lower denomination column
and the higher pH values in the higher denomination columns. Few
exceptions to this rule are due to space constraints, as we chose to give
the screen a larger variation in the use of precipitants rather than the
pH. As final criteria, the salt used in each formulation was considered
in order to further expand the conditions for the screen. Based on our
PDB analysis, themost abundant monovalent and divalent cations that
we included in our formulation are Na+ and Mn2+, respectively.
However, we also tried to include the largest number of salts and
concentrations possible for each precipitant of the screen. Additives
have also been included in some conditions in minute amounts andwe
placed the same condition with and without additives in adjacent
wells. The complete formulation of the RdRp screen is shown in
Table 1. The details of well compositions with volumes of each
component used are shown in Table S2. The source and stock
solutions of each chemical used in the screen are listed in Table S3.
Crystallization results
To validate the RdRp screen developed, we tested whether we could
obtain crystals of DENV serotype 3 RdRp. This protein appeared to
be a highly promiscuous crystallizer: crystals were obtained in 36
distinct conditions, more than a third of all crystallization conditions
provided in our screen. A selection of photos of the crystals is shown
in Fig. 3. Most of the crystals grew within 2–4 days to a size
sufficient to examine their diffraction potential; however, in order to
obtain larger crystals, crystals obtained from the initial screen in
nano-drops were next grown under the same conditions in micro-
drops, without further optimization.
The most successful precipitant agent was found to be PEG (in
accordance with the PDB analysis), present at an average
concentration of 20% in 24 of the 36 conditions that yielded
crystals. Specifically, PEG with a chain length of 4000 was most
prevalent amongst the successful conditions. The pH range covered by
conditions containing PEG varied largely between 4.7 and 8.5, but the
majority of the crystals were obtained at pH values of 5.0, 6.5 and 8.0.
There appears to be no correlation between the formation of crystals
and the buffer used tomaintain the pH,with avarietyof buffers used in
the successful conditions, including Tris, Bis-Tris propane, MES,
acetate and citrate buffers. Similarly, salt in the crystallization
conditions seemed to have a minimal effect on crystal formation.
Crystals obtained in PEG-containing conditions were observed to
be variable in shape and size, with most appearing as single crystals.
Thirteen conditions out of the 24 provided high quality data better or
equal to 3.0 Å to determine their structures, whereas the remaining
crystals either showed no diffraction or diffraction at a much lower
resolution not suitable for structure solution (Table S4).
The second most successful precipitant agents for obtaining
protein crystals were salts such as, for example, sodium-potassium
tartrate, sodium chloride and sodium malonate. All but one yielded
resolution of less than 3.0 Å. Four conditions containing ammonium
sulfate generated crystals, from one of these we were able to collect
diffraction data and solve the structure at 3.0 Å.Others conditions had
crystals which were either too small to measure at an X-ray source, or
diffracted to a lower resolution needing further optimization. The pH
range covered by these conditions was between 6.0–9.5 and was
maintained using a variety of buffers [Tris, HEPES,MMT (DL-malic
acid, MES and Tris base in the molar ratios 1:2:2) and sodium
cacodylate]. Again, crystals obtained under these conditions were
single and variable in shape and size. Diffraction details of the
crystals obtained are shown in Table S4. In total, we identified 13
different conditions yielding high quality RdRp crystals, which
needed no further optimization to obtain the structures. Protein
crystals that would have required further optimization of their
crystallization conditions were not pursued further.
Diffraction data quality analysis from various screen
conditions
A summary of the details of crystals obtained is shown in Fig. 3 and
Table S4. Previously published crystallization conditions of dengue
RdRp3 are represented in the screen in wells C2 (Ref.: PDB ID
2J7U) and D1 (Ref.: PDB ID 4HHJ), both of which resulted in good
diffracting crystals with resolution of 2.3 Å and 2.1 Å, respectively.
Interestingly, some of the conditions consistently produced crystals
within a high-resolution range. The resolution obtained for these
screen conditions are summarized in Fig. 1B.
From the diffraction pattern of the 88 crystals measured at either
12% or 14% glycerol we could conclude that 14% glycerol was
optimal for cryoprotection of these crystals. 12% glycerol as a
cryoprotectant was not sufficient as it resulted in ice rings (Fig. 1C)
for the majority of crystals and also resulted in loss of resolution.We
have collected complete datasets using both 12% and 14% glycerol
and the quantitative representation of the formation of ice rings at
different glycerol concentrations is presented in Fig. 1D.
Data processing and structure determination
Data were processed and reduced using either iMosflm (Battye
et al., 2011) or XDS (Kabsch, 2010) and SCALA from the CCP4
4
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suite of programs (Winn et al., 2011). The structures of dengue
RdRp3 were solved by molecular replacement (PHASER MR in
CCP4 suite) using the native RdRp3 structure (PDB code 4HHJ,
Noble et al., 2013) as a search model. All structures were initially
refined with REFMAC5 (Murshudov et al., 1997). Electron
density and difference density maps, all σA-weighted, were
inspected, and the models were improved using Coot (Emsley and
Cowtan, 2004). The refinement of the structures was performed
using PHENIX (Adams et al., 2010). The calculation of Rfree used
5% of data. Crystallographic and refinement statistics are given in
Table S5. A list of residues missing in the models and the number
of PEG ions as well as water molecules identified are summarized
in Table S6.
Surprisingly, all crystals except one crystallize in space group
C2221, indicating that the varying crystallization conditions exert
no influence on the crystal packing. The architecture of the RdRp
structures obtained from the screen adopts the right-hand
conformation consisting of fingers, palm and thumb domain
(Yap et al., 2007) (Fig. 1A). The structures attain the same closed
conformation with loops from motif G (∼405–420) and motif F
(∼450–470) missing in all the structures originating from the
screen. All our crystal structures contain two zinc binding
pockets represented as blue spheres in the finger and thumb
subdomains, respectively (Fig. 1A), which have a tetrahedral
coordination geometry as previously described (Yap et al., 2007;
Noble et al., 2013).
One structure (PDB ID 2J7U) has one PEG molecule adjacent to
Trp823, whereas the second structure (PBD ID 4HHJ) has three
PEG entities and one additional P6G (longer ethylene glycol chain)
bound to the structure. Twelve of our 13 structures contain PEG
molecules but the number of PEGs varies depending on the
crystallization condition. We could not establish a relationship
between the number of PEG ions present in the structure and the
type of PEG used in the crystallization condition. We also could not
correlate the number of PEG ions and the resolution of the crystals
(Table S5). The role of PEG in the structures is difficult to decipher
but the best assumption is that they stabilize the interaction with
symmetry-related molecules as most of them are present at the
interface of the unit cell and a symmetry related molecule (Fig. 1E).
Overall we conclude that, along with the previous established
conditions of dengue RdRp3, we have now found 11 additional
conditions, which provide reproducible high-resolution structures
without further need for optimization of the crystals. These
conditions provide the best diffraction quality crystals with good
statistics and therefore can be used for small molecule and fragment
crystallization assays. We identified a variety of additional
crystallization conditions, but these would require further
optimization to obtain structures. Although in this study we
obtained a large number of high quality crystals at 18°C, the
possibility of using the screen at other temperatures has not been
tested for DENV3 RdRp. Until recently there were no crystal
structures available for the other serotypes of dengue virus. Recently
Fig. 3. Light micrographs of some of the crystals obtained with the RdRp screen. The images shown represent a selection of crystals obtained directly
from the screen, without further optimization of the conditions. The well numbers for each crystal image are displayed at the top left corner. The last panel
represents RdRp2 crystals obtained in wells F10, F11 and F12, respectively. Magnifications depicted here may differ among the crystal images. Crystal sizes
typically vary from 20–300 μm.
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a structure of dengue RdRp serotype 2 in complex with a small
molecule has been published (Lim et al., 2016). In line with the
previously published structure we also obtained crystals for dengue
RdRp serotype 2 in various conditions at 4°C; however, these
crystals were not single (Fig. 3) and diffracted between 4.0 to 5.0 Å
resolution (not shown). Optimization of these conditions is now in
progress to obtain single high-quality crystals. Therefore, our RdRp-
specific crystallization screen can provide an additional avenue and
starting point for the discovery of successful conditions for RdRp
proteins or RdRp-ligand complexes.
Description of the structure of the RdRp3-PC-79-SH52
complex obtained by soaking and co-crystallization
techniques
The complex structures obtained by co-crystallization (PDB ID:
6H80) and by soaking (PDB ID: 6H9R) are practically identical.
They were both obtained using the well condition C1 and C2 from
our screen. Both RdRp3 structures lack residues 312–318, 343–354,
406–418, 454–469 and 581–586. The PC-79-SH52 fragment is
bound in the palm domain of RdRp protein as previously described
(Noble et al., 2016). A significant proportion of the binding is
driven by hydrophobic interactions mediated by the thiophene and
phenyl ring systems. The sulphur atom of PC-79-SH52 interacts
with the side chains of Ala799, Ser796 and Leu511. The thiophene
ring points towards the predominantly hydrophobic portion of the
inhibitor-binding pocket formed by His711, Met761, Met765,
His798 and Trp803. The phenyl moiety also has hydrophobic
interactions with Arg729 and Cys709. The carboxyl group forms
key hydrogen bonding interactions mediated by water molecules
with main chains atoms of Thr794 and Trp795 (Fig. 4; Fig. S1).
Overall, the structure of the RdRp3 in complex with the PC-79-
SH52 fragment is similar to the previously published structure
(PDB ID: 5F3Z; Noble et al., 2016). Therefore we conclude that our
screen will also be suitable for future studies on structure-based drug
design targeting RdRps.
DISCUSSION
Certain members of the Flaviviridae family are important global
pathogens raising significant public health concerns. Their
RNA-dependent RNA polymerases represent key targets to treat
infections and are intensively studied since there are no mammalian
homologues.
The RdRp screen was developed and validated by crystalizing
dengue RdRp serotypes 2 and 3, and serotype 3 in complex with a
known fragment. PEG molecules of various molecular weights
appeared to be the most successful precipitant, in particular PEG
4000. RdRp3 is a promiscuous crystallizer and crystals were obtained
in 36 out of 96 distinct conditions, 13 of which did not need any
further optimization, yielding crystals diffracting to a high resolution
(2.0–3.0 Å). Thirteen complete data sets were collected and structures
were obtained from all these data sets.
We believe this study provides a promising platform to screen and
crystallize polymerases from other viruses, including emerging
RNA viruses such as ZIKV. Studies using the RdRp screen to
crystallize the serotypes 1 and 4 of dengue RdRp are underway.
Indeed, it will be interesting to observe if optimal crystallization
conditions are shared amongst the different serotypes, given their
high structural similarity. This screen, which is convenient, fast and
Fig. 4. Structure of RdRp3 in complex with its inhibitor. (A) Graph representing the DMSO concentration plotted against the resolution using native DENV
RdRp3 crystals at 1 h (●) and 3 h (▪) incubation time (n=12, mean±s.d.). This allowed us to determine the optimal percentage of DMSO and fragment that
can be employed for soaking, data collection and subsequent structure determination. (B) Overall superimposition of the structure of the RdRp3 domain in
complex with PC-79-SH52 obtained via co-crystallization (green) and soaking (cyan). There are no obvious differences in the two structures or binding
conformations of the inhibitor. Magnification of the inhibitor-binding pocket in the Palm domain as a surface with bound PC-79-SH52. (C) The electron-
density of the ligand Fo-Fc difference electron density (contoured at 3σ) is shown as a grey mesh with the inhibitor via co-crystallization (blue) and soaking
(magenta). (D) Chemical structure of PC-79-SH52.
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cheap, can be used as a first attempt to crystallize novel RdRps to
facilitate an understanding of the fundamental processes underlying
the replication of viral genomes.
Importantly, the screen presented in this study can be used for the
crystallization of RdRp-ligand complexes and therefore will support
structure-based design to develop novel RdRp inhibitors. The crystal
structures of RdRp3 in complex with PC-79-SH52 prove how this
new crystallization screen can be used for structure-based drug design
against RdRps targets. We have obtained nearly identical complex
structures using both co-crystallisation of RdRp3 with PC-79-SH52
or soaking native RdRp3 at high concentrations of the fragment.
Therefore, our screen is versatile and flexible in using either of the
methods for determining future ligand complex structures of RdRps
for structure-based drug design. Traditionally, glycerol has been used
as a cryo-protectant for diffractionmeasurements of RdRp crystals. In
our case, we optimized theminimum percentage glycerol required for
measuring dengue RdRp3 crystals obtained under various conditions
in our 96-well screen. The majority of ligands that are used for
soaking or co-crystallization experiments are usually dissolved in
DMSO. Interestingly, in our soaking experiments we could show that
diffraction measurements of RdRp complexes do not require any
additional cryo-protectant. Optimization of the tolerance levels of
RdRp crystals at increasing DMSO concentrations resulted in 10%
DMSO at an incubation time of 1–3 h for optimal experimental
conditions (Fig. 4A). This serves two purposes, first the best
condition can be used to soak native crystals with high concentrations
of inhibitors/fragments in DMSO,without destroying the crystals and
thereby increasing the changes of obtaining co-crystal structures for
weak binders. Secondly, the soaking, freezing, and data collection
pipeline of RdRp crystals is straightforward.
In summary, our screen provided a variety of novel crystallization
conditions leading to highly reproducible and high quality RdRp
crystals, which are suitable not only for structure-based design, but
also for direct crystallization-based fragment screening. In addition,
although we did not obtain high quality crystals for RdRp2,
optimising the initial crystallisation condition may lead to suitable
crystals for structure determination.
MATERIALS AND METHODS
Data mining, analysis of the PDB and the design of the RdRp
Screen
The deposited structures of RdRps (alone or in complex with ligands)
solved by X-ray crystallography were retrieved and analyzed from the PDB
crystallographic database (www.rcsb.org). The details of this database
search, which is the basis of this study, are shown in Table S1. The details of
the design and development of the screen in 96-well format taking into
account all published conditions are shown in Table 1.
Chemistry
The RdRp inhibitor PC-79-SH52 was synthesized as previously described
(Noble et al., 2016; Yokokawa et al., 2016).
Cloning, expression and purification of Rdrp3 from dengue virus
DENV RdRp serotype 3 (residues 265–900) was amplified from DENV
strain D3/SG/05K/2005, previously subcloned into pcDNA3.1 (kind gift
from A. Davidson, University of Bristol) using CloneAmp HiFi PCR
Premix (Clontech Laboratories, Inc.) as per the manufacturer’s instructions
(forward primer: AAGTTCTGTTTCAGGGCCCG.AATGCGGAACCA-
GAAACACCC; reverse primer: ATGGTCTAGAAAGCTTTA.CCAAA-
TGGCTCCCTCCGACTC). DENV RdRp serotype 2 (residues 266–900)
was amplified from DENV strain D2/NGC, previously subcloned into
pcDNA3.1 (kind gift from A. Davidson, University of Bristol) using the
same procedure as for RdRp serotype 3 (forward primer: AAGTTCTG-
TTTCAGGGCCCG.GGAATTGAAAGTGAGATACCA; reverse primer:
ATGGTCTAGAAAGCTTTA.CCACAGGACTCCTGCCTCTTC). After
purification of the PCR products, the amplified fragments were cloned by
recombination into a pOPINF vector, linearized with KpnI and HindIII
restriction enzymes (New England Biolabs), using the In-Fusion® HD
Cloning Kit (Clontech Laboratories, Inc.) as per the manufacturer’s
instructions. DNA sequencing using a T7 primer was used to verify the
presence and correct insertion of the constructs.
Escherichia coli BL21(DE3) pLysS cells were transformed with the
recombinant plasmid carrying the gene encoding DENV RdRp serotype 3
whereas BL21(DE3) cells were transformed with DENV RdRp serotype
2. Both the proteins were expressed by growing the cells at 37°C in Terrific
Broth medium containing 100 mg/l ampicillin until the A600 was 0.9–1.2.
Protein expression was induced for 22–24 h at 20°C by adding 0.5 mM
IPTG (isopropyl-β-D-thiogalactopyranoside). Cells were then harvested by
centrifugation at 8000 rpm for 10 min at 4°C and the cell pellets were stored
at −80°C.
Cell pellets were resuspended in buffer A (20 mM HEPES, pH 7.5,
500 mMNaCl, 0.01%Tween-20 and 10 mM Imidazole) supplemented with
1 mM PMSF and 2 mg/ml DNase I, lysed by sonication and the lysate was
clarified by centrifugation at 20,000 rpm for 1 h 30 min at 4°C.
The supernatant was loaded onto a 5 ml Ni-NTA His-Trap FF crude
column (GE Healthcare), pre-equilibrated with buffer A. Unbound proteins
were washed away with five column volumes of buffer B containing all
components of buffer A, but 30 mM imidazole instead of 10 mM, and the
protein was eluted with buffer C (buffer A plus 250 mM Imidazole).
Fractions containing the desired protein were detected by using Bradford
reagent for qualitative measurement that were later pooled and dialyzed
overnight against buffer D (20 mM HEPES, pH 7.5, 0.5 M NaCl, 0.01%
Tween-20) together with 3C protease (1 mg of 3C protease for 50 mg of
protein) and 3 mM DTT to remove the hexa-histidine tag.
Uncleaved protein and protease were removed by running the sample
through a Ni-NTA HisTrap column for a second time. The cleaved protein,
which did not bind to the column material, was pooled and the buffer was
Table 2. Data collection, structure determination and refinement
statistics for the dengue RdRp3-PC-79-SH52 complexa
Statistics Soaking Co-crystallization





Resolution range [Å] 48.8–2.4 52.7-2.3






Completeness [%] 99.0 (99.8) 99.8 (99.1)
Rmerge 5.3 (46.4) 3.2 (48.2)
Multiplicity 2.0 (2.0) 2.0 (2.0)
Mean I/σ(I) 10.6 (2.1) 15.6 (2.0)
CC1/2 99.6 (77.4) 99.9 (80.9)
Total reflections 68,338(6679) 78,203(7695)
Unique reflections 34,409(3371) 39,134(3850)
WILSON B-FACTOR (Å2) 40.2 49.8
Refinement statistics






No. of PEG/inhibitor/water 8/1/195 5/1/169
r.m.s.d. bond lengths [Å] 0.013 0.013
r.m.s.d. bond angles [˚] 1.44 1.45




aValues in parentheses pertain to the highest-resolution shell.
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exchanged with buffer E (50 mM HEPES, pH 7.5 and 0.5 M NaCl). All
stages of protein purification were analysed by running samples on SDS-
PAGE. The obtained protein was concentrated by ultrafiltration using a
Centricon 30 kDa MWCO (Millipore) to reach a final concentration of
10 mg/ml. Finally, the protein was aliquoted in 50 µl aliquots, frozen in
liquid nitrogen and stored at −80°C to be used for subsequent
crystallization.
The same protocol was followed for DENVRdRp serotype 2 purification,
but the following buffers were used: Buffer A1 (50 mM Tris, pH 8.8,
500 mMNaCl, 0.01%Tween-20 and 10 mM Imidazole), buffer B1 (50 mM
Tris, pH 8.8, 500 mM NaCl, 0.01% Tween-20 and 30 mM Imidazole),
buffer C1 (50 mM Tris, pH 8.8, 500 mM NaCl, 0.01% Tween-20 and
250 mM Imidazole) for affinity purification. Buffer D1 (50 mM Tris, pH
8.8, 0.5 M NaCl, 0.01% Tween-20) was used for overnight dialysis and
cleavage with 3C-protease and was buffer-exchanged into buffer E1
(50 mM Tris, pH 8.8 and 0.5 M NaCl) for setting up crystallization trails.
Protein crystallization trials, optimization for diffraction
measurements
Crystallization trails were carried using the newly developed RdRp screen
with RdRp serotype 3 at 10 mg/ml using a Mosquito Crystal (ttp Labtech)
nano-drop robot and 96-well 3-drop Swissci plates (Molecular Dimensions)
applying the vapour diffusion sitting drop method.
For the initial screen an equal volume of protein sample and well solution
were mixed (100 nl:100 nl). Plates were then incubated at 291K (18°C) for
several weeks with regular visual examination. Crystals were obtained in
most of the drops within 2–4 days.
Diffraction quality single crystals for each successful condition were
obtained using Crystalgen SuperClear™ Plates pre-greased 24-well linbro
plates (Jena Biosciences). The drops were set up using 1 μl of protein
(10 mg/ml) and 1 μl of well solution using the hanging drop vapour
diffusion method.
Crystallization trials for RdRp serotype 2 were set up using the screen by
mixing an equal volume of protein sample and well solution (e.g.
100 nl:100 nl). Plates were then incubated at two distinct temperatures at
277K (4°C) and 291K (18°C) for several weeks with regular visual
examination. Crystals were obtained in most of the drops within 2–4 days at
18°C and after about 2 weeks at 4°C.
To obtain a co-crystal structure of RdRp serotype 3 in complex with
PC-79-SH52 (Noble et al., 2016) using co-crystallization, the protein was
incubated with 1 mM of the inhibitor for 1 h at 4°C before setting up
crystallization drops.
Determination of inhibitor soaking conditions for optimal
diffraction measurements for RdRp serotype 3-inhibitor
complexes
The RdRp serotype 3 inhibitor was provided as a 50 mM DMSO stock. For
soaking experiments, we initially wanted to obtain the optimal DMSO
concentrations and soaking times required without affecting the diffraction
quality of our crystals. The graph in Fig. 4A shows how the diffraction
quality varies with different DMSO concentrations present in the soaking
solutions for different lengths of the soaking time. We determined soaking
crystals with compound PC-79-SH52 at 10% DMSO for 1 h to be optimal.
To increase our chances in obtaining RdRp3-inhibitor complex via soaking
of native crystals with the inhibitor, we tested two different final
concentrations of the inhibitor at 20 and 40 mM (maintaining 10% overall
DMSO concentration).
For data collection, crystals were frozen in the presence of DMSO, which
acted as a cryoprotectant. The crystals were then flash frozen in liquid
nitrogen for subsequent measurements using synchrotron radiation.
Data collection, structure determination
Diffraction data for each individual crystal were collected on Massif
beamline ID30a-1 at the ESRF and at beamlines I03 and I04 at Diamond
Light Source. Data were processed using either XDS (Kabsch, 2010) or
iMosflm (Battye et al., 2011) and scaled to resolutions as mentioned in
Table S4 (Winn et al., 2011). The structure of the dengue RdRp serotype 3
was solved by molecular replacement. Further details are provided in the
section 3.4.2 and the crystallographic statistics are given in Table S5.
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Table S1 Data mining for RdRp crystallization conditions. The details of each RdRp structure submitted to the PDB were individually extracted to design 
the RdRp screen.  
N° Organism Protein PDB Id Resolution
(Å) 
Space group Method & Temperature 
(°C) 
Crystallization condition PMID & references 
1 Bovine viral 
diarrhea virus 
RdRp 2CJQ 2.60 P31 Sitting drop 10% PEG 8000  
0.1 M HEPES, pH 7.5  
8% Ethylene Glycol 
(Choi et al., 2006) 
2 Coxsackievirus B3 
Polymerase 
F232L mutant 
4WFX 1.81 P43212  (16°C) 0.085 M HEPES,  
3.655 M NaCl,  
15% Glycerol 
(Campagnola et al., 
2015) 
3 Coxsackievirus B3 
Polymerase 
F232L mutant 
4WFY 2.06 P43212  (16°C) 0.085 M Tris, pH 7.5,  
1.275 M (NH4)2SO4,  
25% Glycerol 
4 Coxsackievirus B3 3D pol 
RdRp 
4WFZ 1.80 P43212  (16°C) 0.085 M HEPES, pH 7.5 
3.6 M NaCl, 15% Glycerol 
5 Coxsackievirus B3 3D pol 
with GPC-
N114 inhibitor 
4Y2A 2.90 P43212 Sitting drop (20°C) 50 mM Tris, pH 7.5  
24.5% Glycerol 
1.29 M (NH4)2SO4 
(van der Linden et 
al., 2015) 
6 Coxsackievirus B3 3D pol in 4Y34 2.70 P43212 Sitting drop (20°C) 50 mM Tris pH 7.5 
































1.2 9 M (NH4)2SO4 
7 Coxsackievirus B3 RdRp (3D 
pol) with 
pyrophosphate 
3CDU 2.10 P43212 Hanging drop (20°C) 2 M (NH4)2SO4,  
0.1 M CAPS, pH 10.0, 
0.2 M Li2SO4 
(Gruez et al., 2008) 
8 Coxsackievirus B3 RdRp (3D 
pol) with 
protein primer 
VPg and a 
pyrophosphate 
3CDW 2.50 P43212 Hanging drop (20°C) 2 M (NH4)2SO4,  
0.1 M CAPS, pH 10.0 
0.2 M Li2SO4 
9 Dengue virus 
serotype 3 
NS5 RdRp 2J7U 1.85 C2221 Hanging drop (4°C) 0.1 M Tris-HCl, pH 8.5  
0.8 M K/Na Tartrate  
0.5% PEG 5000 MME 
(Yap et al., 2007) 
 





2J7W 2.60 C2221 Hanging drop (4°C) 0.1 M Tris-HCl, pH 8.5 
0.8 M K/Na Tartrate, 
0.5% PEG 5000 MME 




1.79 C2221 Hanging drop (18°C) 0.1 M Tris, pH 8.0 
25% PEG 550 MME 
(Noble et al., 2013) 




3VWS 2.10 C2221 Hanging drop (18°C) 20% PEG 550 MME 
0.1 M Tris pH 8.0 
































the NS5 linker 
region 
4C11 2.60 P21212 Sitting drop (20°C) 1.0 M Succinic Acid, 
0.1 M HEPES, pH 7.0 
1% PEG 2000 MME 
(Lim et al., 2013) 





5F3Z 2.00 C2221 Hanging drop (18°C) 0.1 M Tris, pH 8.0 
25% PEG 550 MME 
(Noble et al., 2016) 




5F41 2.00 C2221 Hanging drop (18°C) 





5F3T 2.05 C2221 Hanging drop (18°C) 





4V0Q 2.30 P21212 Sitting drop (20°C) 0.2 M CaAc2 or MgAc2 
0.1 M Na Cacodylate, pH 6.4 
10-20% PEG 8000 
(Zhao et al., 2015) 




GTP and SAH 
4V0R 2.40 P21212 Sitting drop (18°C) 0.1 M Na Cacodylate, pH 6.4 
0.2 M MgAc2 or CaAc2 
14% PEG 8000 
19 Enterovirus 71 RdRp 3N6L 2.60 P3221 Hanging drop (18°C) 1.3 M (NH4)2SO4 
1 mM DTT  
(Wu et al., 2010) 
20 Enterovirus 71 RdRp 3N6M 2.50 P3221 Hanging drop (18°C) 





























21 Enterovirus 71 RdRp 3N6N 2.90 P3221 Hanging drop (18°C) 0.1 M Bis-Tris pH 6.1  
10 mM NiCl2 
 





4WZM 2.57 P3221 Hanging drop (20°C) 30% PEG 4000  
0.2 M MgAc2, 
0.1 M MES pH 6.0  
4% γ-butyrolactone 
 
(Ferrer-Orta et al., 
2015) 
23 Foot and mouth 
disease virus 
3D pol K18E 
mutant 
4WYL 2.00 P41212 Hanging drop (20°C) 
24 Foot and mouth 
disease virus 
3D pol K20E 
mutant 
4WYW 1.80 P41212 Hanging drop (20°C) 





4WZQ 2.80 P3221 Hanging drop (20°C) 30% PEG 4000 
0.2 M MgAc2 
0.1 M MES pH 6.0 
26 Foot and mouth 
disease virus 
RdRp K20A 
mutant with an 
RNA 
4X2B 2.94 P41212 Hanging drop (20°C) 
27 Foot and mouth 
disease virus 




2E9R 2.81 P3221 Hanging drop (20°C) 30% PEG 4000  
0.2 M MgAc2 
0.1 M Na Cacodylate  
pH 6.0 
(Ferrer-Orta et al., 
2007) 
28 Foot and mouth 
disease virus 
RdRp with a 
template-
2E9T 2.60 P3221 Hanging drop (20°C) 






























29 Foot and mouth 
disease virus 




2EC0 2.70 P3221 Hanging drop (20°C) 33% NH4Ac 
0.1 M Na Citrate pH 5.6 
4% butyrolactone 





2F8E 2.90 P3221 Hanging drop (20°C) 33% PEG 4000  
0.2 M NH4Ac 
0.1 M Na Citrate, pH 5.6 
4% Butyrolactone 
(Ferrer-Orta et al., 
2006) 




2D7S 3.00 P3221 Hanging drop (20°C) 
32 Hepatitis C virus NS5B RdRp 1C2P 1.90 P212121 Batch (22°C) 10% PEG 4000, 10% Glycerol, 
5 mM DTT, 5 mM Tris, pH 7.5, 
25 mM MES, pH 5.0 
(Lesburg et al., 
1999) 
33 Hepatitis C virus RdRp 1CSJ 2.80 P212121 Hanging drop (4°C) 5% PEG 8000, 5% 2-propanol  
0.1 M Na Citrate, pH 6.5 
34 Hepatitis C virus RNA pol in 
complex with 
GTP and Mn2+ 
1GX5 1.70 P212121 Hanging drop (4°C) 4% PEG 4000  
7% 2-Propanol  
0.1 M Na Citrate, pH 6.8  
(Bressanelli et al., 
2002) 
35 Hepatitis C virus RNA pol in 
complex with 
1GX6 1.85 P212121 Hanging drop (4°C) 





























UTP and Mn2+ 





1NHU 2.00 P212121 Hanging drop (22°C) 18% PEG 4000 
0.3 M NaCl  
0.1 M NaOAc, pH 5.0,  
0 5 mM 2-mercaptoethanol 
(Wang et al., 2003) 
37 Hepatitis C virus RNA pol with 
NNI 
1NHV 2.90 P212121 Hanging drop (22°C) 




1OS5 2.20 P41212 Hanging drop (20°C) 0.2 M NH4Ac, pH 4.6 
30%  PEG MME 2000 
(Love et al., 2003) 
39 Hepatitis C virus RdRp 1QUV 2.50 P43212 Hanging drop (22.5°C) 21 – 28% PEG 4000, 0.2 -0.35 
M NaOAc, 0.1M NH4Ac 
0.02 M TES, pH 6.0 
(Ago et al., 1999) 
40 Hepatitis C virus NS5b RNA 
Pol with a 
covalent 
inhibitor 
2AWZ 2.15 P212121 Hanging drop (20°C) 200 mM (NH4)2SO4   
27% PEG 5000 MME  
100 mM NaOAc, pH 5.0 
 
(Powers et al., 2006) 
41 Hepatitis C virus NS5b Pol with 
a covalent 
2AX1 2.10 P212121 Hanging drop (20°C) 






























42 Hepatitis C virus Pol with an 
allosteric 
inhibitor 
2BRK 2.30 P21212 Hanging drop (4°C) 5% PEG 8000  
5% 2-propanol  
0.1 M Na Citrate, pH 6.5 
 
(Di Marco et al., 
2005) 
43 Hepatitis C virus Pol with an 
allosteric 
inhibitor 
2BRL 2.30 P21212 Hanging drop (4°C) 
44 Hepatitis C virus NS5B pol with 
a tetracyclic 
inhibitor 
2DXS 2.20 P121 Hanging drop (4°C) 0.1 M Citrate, pH 5.5  
8% PEG 8000  
5% 2-propanol 
(Ikegashira et al., 
2006) 
45 Hepatitis C virus NS5B RdRp 
with NNI-2 
inhibitor 
2GIQ 1.65 P212121 Hanging drop (20°C) 50 mM Na Citrate pH 4.9  
26% PEG 4000 
7.5% Glycerol 
(Le Pogam et al., 
2006) 
46 Hepatitis C virus NS5B RdRp 
with NNI-1 
inhibitor 
2GIR 1.90 P212121 Hanging drop (20°C) 




2HAI 1.58 P41212 Hanging drop (20°C) 30% PEG MME 2000, 
0.2 M (NH4)2SO4  
0.1 M NH4Ac, pH 5.0 
(Li et al., 2006) 
48 Hepatitis C virus NS5B pol with 
Thiazolones 
2I1R 2.20 P212121 Evaporation (22°C) 20% PEG 400 
5 mM DTT  
(Yan, Larson, et al., 
2007) 




























inhibitor 0.5 M MES, pH 5.0 
1.0 M NaCl 
49 Hepatitis C virus NS5B 
polymerase 
2IJN 2.20 P212121 Evaporation (22°C) 20% PEG 4000  
5 mM DTT  
0.5 M MES, pH 5.0 
1.0 M NaCl 
(Yan, Appleby, 
Gunic, et al., 2007) 
50 Hepatitis C virus NS5B with 
allosteric 
inhibitor 
2HWH 2.30 P212121 Evaporation (22°C) 20% PEG 4000  
5 mM DTT  
0.5 M MES, pH 5.0 
1.0 M NaCl 
(Yan et al., 2006) 
51 Hepatisis C virus NS5B with 
allosteric 
inhibitor 
2HWI 2.00 P212121 Evaporation (22°C) 
52 Hepatisis C virus Polymerase 
with inhibitor 
SB655264 
2JC0 2.00 P212121 20% PEG 4000,  
5 mM DTT,  
10% Glycerol  
0.1 M Citrate buffer, pH 5.0 
(Slater et al., 2007) 
53 Hepatisis C virus Polymerase 
with inhibitor 
SB698223 
2JC1 2.00 P212121 




2O5D 2.20 P212121 Evaporation (22°C) 20% PEG 4000  
5 mM DTT  
0.5 M MES, pH 5.0 
(Yan, Appleby, 
Larson, et al., 2007) 





























inhibitors 1.0 M NaCl 




2XI2 1.80 P 21 Sitting drop  0.1 mM MES, pH 6.5  
0.2 M (NH4)2SO4   
PEG 5000 MME 
(Harrus et al., 2010) 





2XI3 1.70 P1 Sitting drop 0.05 M MES, pH 6.5, 0.2 M 
(NH4)2SO4  
0.25 M NH4Ac  
25%-30% PEG 1000 




2WCX 2.00 P21212  0.1 M MES, pH 6.0  
14% PEG 8000  
14% 2-propanol  
10 mM DTT,  
10 mM MnCl2 
(Martin Hernando et 
al., 2009) 
58 Hepatitis C virus 
genotype 1B 
NS5B pol with 
a NNI 
2WHO 2.00 P212121  0.1 M MES, pH 6.0  
14% PEG 8000  
14% 2-propanol  
10 mM DTT  
10 mM MnCl2 
 
(Ontoria et al., 2009) 
59 Hepatitis C virus NS5B pol with 
an allosteric 
2WRM 1.95 P21212  pH 6.0 To be published 




































2XWY 2.53 P21212  0.1 M MES, pH 6.0 
14% PEG 8000  
2.5 mM TCEP 
14% 2- propanol  
10 mM MnCl2 
 
 (Narjes et al., 2011) 
61 Hepatitis C virus NS5B 
polymerase 
2ZKU 1.95 P212121 Hanging drop (25°C) 5 mM 2- Mercaptoethanol  
18% PEG 4000  
0.3 M NaCl 
0.1 M NaOAc, pH 5.0 
 




3I5K 1.90 P21 Hanging drop (20°C) 6 to 7% PEG 20000 
0.2 M NaH2PO4, pH 7.0 
 
(Simister et al., 
2009) 




3BR9 2.30 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4 
0.1 M NaOAc, pH 7.4 
 
(Zhou et al., 2008) 
64 Hepatitis C virus NS5B pol with 
a novel 
Pyridazinone 
3BSA 2.30 P212121 Hanging drop (25°C) 

































3BSC 2.65 P212121 Hanging drop (25°C) 




3CDE 2.10 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT  
50 mM (NH4)2SO4  
0.1 M NaOAc 
(Li et al., 2008) 




3CIZ 1.87 P212121 Hanging drop (19°C) 8-11% Glycerol 
20-24% PEG 4000  
50 mM Na Citrate, pH 4.9 
(Antonysamy et al., 
2008) 




3CJ0 1.90 P212121  (19°C) 




3CJ2 1.75 P21  (19°C) 
70 Hepatitis C virus NS5B RdRp 3CJ3 1.87 P212121  (19°C) 




































3CJ4 2.07 P21  (19°C) 




3CJ5 1.92 P212121  (19°C) 




3CO9 2.10 P212121  (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 
(Ruebsam et al., 
2008) 




3CVK 2.31 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 
(Ellis et al., 2008) 
75 Hepatitis C virus NS5B pol with 
a novel 
Pyridazinone 
3CWJ 2.40 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
 
(Ellis et al., 2008) 





























inhibitor 50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 




3D28 2.30 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 
 
(Kim et al., 2008) 




3D5M 2.20 P212121 Hanging drop (25°C) 




3E51 1.90 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 
(Dragovich et al., 
2008) 
79 Hepatitis C virus NS5B pol with 
796 inhibitor 
3FQK 2.20 P212121 Hanging drop (20°C) 50 mM Na Citrate, pH 4.9  
7.5% Glycerol  
24% PEG 4000 
(Hang et al., 2009) 
80 Hepatitis C virus NS5B pol with 
796 inhibitor 
3FQL 1.80 P212121 Sitting drop (20°C) 50 mM Na Citrate pH 4.9  
7.5% Glycerol 
26% PEG 4000 




























81 Hepatitis C virus NS5B RNA 
pol with 
PF868554 
3FRZ 1.86 P41212 Hanging drop (25°C) 18.0% PEG 3000  
14% Glycerol 
0.1 M Citrate, pH 5.5 
(Li et al., 2009) 
82 Hepatitis C virus NS5B pol with 
thiazine 
inhibitor 
3G86 2.20 P212121 Sitting drop 50 mM Na Citrate pH 4.9 
7.5% Glycerol  
24% PEG 4000 
(de Vicente et al., 
2009) 





3GYN 2.15 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 
(Ellis et al., 2009) 





3IGV 2.60 P212121 Hanging drop (25°C) 





3H2L 1.90 P212121 Hanging drop (25°C) 20% PEG 4000  
5 mM DTT 
50 mM (NH4)2SO4  
0.1 M NaOAc, pH 4.7 
(Ruebsam et al., 
2009) 
86 Hepatitis C virus NS5B pol 3H59 2.10 P212121 Hanging drop (20°C) 50 mM Na Citrate pH 4.9 






























26% PEG 4000  
7.5% Glycerol 
(de Vicente, et al., 
2009) 
87 Hepatitis C virus NS5B pol with 
saccharin 
inhibitor 
3H5S 2.00 P212121 Sitting drop (20°C) 50 mM Na Citrate, pH 4.9  
26% PEG 4000  
7.5% Glycerol 
88 Hepatitis C virus NS5B pol with 
saccharin 
inhibitor 1 
3H5U 1.95 P212121 Sitting drop (20°C) 50 mM Na Citrate, pH 4.9  
24% PEG 3350  
7.5% Glycerol 
89 Hepatitis C virus NS5b 1b with 
a pyrimidine 
derivative 
3H398 1.90 P212121 Sitting drop (20°C) 12-17.5% PEG 4000  
8-11% Glycerol  
0.1 M Na Citrate, pH 4.5-6.0 
(Wang et al., 2009) 
90 Hepatitis C virus NS5B pol with 
thumb site 
inhibitor 
3MF5 2.00 P212121 Sitting drop (0°C) 26% PEG 4000  
7.5% Glycerol  
50 mM Na Citrate, pH 4.9 
(Yang et al., 2010) 
91 Hepatitis C virus NS5B pol with 
3-heterocyclic 
quinolone 
3UDL 2.15 P212121  (18°C) 16% PEG 4000  
10% Glycerol  
0.3 M NaCl  
5 mM ß-mercaptoethanol  
0.1 M NaOAc, pH 5.1 
(Kumar et al., 2011) 





























92 Hepatitis C virus NS5B RNA 
pol with a 
piperazine 
inhibitor 
3QVS 1.90 P212121 Hanging drop (10°C) 0.1 M NaOAc, pH 6.0  
14% PEG 4000  
0.3 M NaCl  
5 mM 2-mercaptoehanol 
2.4 mM n-octanoylsucrose 
(Ando et al., 2012) 





4E7A 3.00 P65 Sitting drop (16°C) 30% PEG 3350 
0.1 M Bis-Tris propane, pH 6.0 
0.2 M NH4Ac 
(Mosley et al., 2012) 





4E78 2.50 P65 Sitting drop (16°C) 





4E76 2.90 P65 Sitting drop (16°C) 30% PEG 550 MME 
0.1 M Bis-Tris propane, pH 6.5 
50 mM (NH4)2SO4 
96 Hepatitis C virus NS5B pol 
inhibited by 
Tri-substituted 
4EO6 1.79 P212121 Sitting drop (20°C) 15-20% PEG 4000 
10% Glycerol, 
(Canales et al., 
2012) 





























acylhydrazines 0.1 M NaOAc, pH 4.8-5.0 




4EO8 1.80 P212121 Sitting drop (20°C) 





4IH5 1.90 P212121 Sitting drop (25°C) 26% PEG 4000 
7.5% Glycerol 
50 mM Na Citrate, pH 4.9 
 
(Talamas et al., 
2013) 





4IH6 2.20 P21 Sitting drop (20°C) 





4IH7 2.30 P212121 Sitting drop (25°C) 
101 Hepatitis C virus NS5B GT1B 
N316 with 
GSK5852A 
4KAI 2.19 P212121 Sitting drop (25°C) 0.1 M Na-citrate pH 5.0 
17% PEG 4000  
(Maynard et al., 
2014) 




























102 Hepatitis C virus NS5B GT1B 
N316Y with 
CMPD 32 
4KB7 1.81 P212121 Sitting drop (25°C) 10% Glycerol 
103 Hepatitis C virus NS5B GT1B 
N316Y with 
CMPD 4 
4KBI 2.06 P212121 Sitting drop (25°C) 
104 Hepatitis C virus NS5B GT1B 
N316Y with 
GSK5852 
4KE5 2.10 P212121 Sitting drop (25°C) 
105 Hepatitis C virus NS5B 1b (BK) 
with RG7109 
4MIA 2.80 P212121 Sitting drop (19°C) 24% PEG 4000  
7.5% Glycerol 
50 mM Na Citrate, pH 4.6 
(Talamas et al., 
2014) 
106 Hepatitis C virus NS5B 1b (BK) 
with 
Compound 48 
4MIB 2.30 P212121 Sitting drop (19°C) 26% PEG 4000  
7.5% Glycerol 
50 mM Na Citrate, pH 4.9 
107 Hepatitis C virus NS5B 1b (BK) 
with inhibitor 
2 
4MK7 2.80 P212121 Sitting drop (19°C) 26% PEG 4000  
7.5% Glycerol 
50 mM Na Citrate, pH 4.9 
(Schoenfeld et al., 
2013) 
108 Hepatitis C virus NS5B 1b (BK) 
with inhibitor 
4 
4MK8 2.09 P212121 Sitting drop (19°C) 




























109 Hepatitis C virus NS5B 1b (BK) 
with inhibitor 
14 
4MKB 1.90 P212121 Sitting drop (19°C) 
110 Hepatitis C virus NS5B 1b (BK) 
with inhibitor 
12 
4MK9 2.05 P212121 Sitting drop (19°C) 26% PEG 4000  
7.5% Glycerol 
50 mM Tris, pH 7.5 
111 Hepatitis C virus NS5B 1b (BK) 
with inhibitor 
13 
4MKA 2.05 P212121 Sitting drop (19°C) 




4OBC 2.50 P65 Sitting drop (16°C) PACT screen condition D5: 
25% PEG 1500  
0.1 M MMT buffer, pH 8.0 
(Lam et al., 2014) 




4ADP 1.90 P212121 17% PEG 4000  
0.05 M Tri-Na Citrate, pH 6.5 (Scrima et al., 2012) 





4RY5 2.71 P212121 Hanging drop (18°C) 50 mM MES, pH 5.0 
20% PEG 4000  
5% Glycerol 
(Cherry et al., 2015) 





4RY6 2.52 P212121 Hanging drop (18°C) 
116 Hepatitis C virus RNA pol 4RY7 3.00 P212121 Hanging drop (18°C) 





























– J4 D559E mutant 








4WT9 2.50 P65 Sitting drop (16°C) 30% PEG 550 MME 
0.1 M HEPES, pH 7.5 
50 mM MgCl2 
(Appleby et al., 
2015) 







4WTA 2.80 P65 Sitting drop (16°C) 25% PEG 550 MME 
0.1 M HEPES, pH 7.5 
50 mM MgCl2 
 







4WTC 2.75 P65 Sitting drop (16°C) 
120 Hepatitis C virus NS5B 2A 4WTD 2.70 P65 Sitting drop (16°C) 










































4WTE 2.90 P65 Sitting drop (16°C) 








4WTF 2.65 P65 Sitting drop (16°C) 
123 Hepatitis C virus NS5B 2A 
JFH-1 with 
S15G, E86Q, 
4WTG 2.90 P65 Sitting drop (16°C) 









































4WTI 2.80 P65 Sitting drop (16°C) 








4WTJ 2.20 P65 Sitting drop (16°C) 
126 Hepatitis C virus NS5B 2A 
JFH-1 with 
S15G, E86Q, 
4WTK 2.50 P65 Sitting drop (16°C) 










































4WTL 2.00 P65 Sitting drop (16°C) 








4WTM 2.15 P65 Sitting drop (16°C) 
129 Hepatitis C Virus RNA pol apo-
form 
1NB4 2.00 P212121 (18°C) 50 mM MES, pH 5.0  
20% PEG 4000 
(O'Farrell et al., 
2003) 
130 Hepatitis C Virus RNA pol with 1NB6 2.60 P212121 (18°C) 





























UTP 10% Glycerol  
5 mM DTT 
 
131 Hepatitis C Virus RNA pol with 
short RNA 
template 
1NB7 2.90 P212121 (18°C) 
132 Human Norovirus RdRp with 
inhibitor 
PPNDS 
4LQ3 2.60 I222 Sitting drop (20°C) 1.2 M Na Citrate  
0.125 M NaCl 
0.1 M Na cacodylate 
(Tarantino et al., 
2014) 
133 Human Norovirus RdRp in 
complex with 
NAF2 
4LQ9 2.04 I222 Sitting drop (20°C) 
134 Human Norovirus Pol bound to 
suramin 
derivative 
4NRT 2.02 I222 Sitting drop (20°C) 1.2 M Na citrate, 
0.125 M NaCl 
0.1 M Na cacodylate, pH 6.2 




RdRp 1TP7 2.40 P21 Sitting drop (22°C) 40% PEG 4000  
0.1 M Na citrate pH 5.6,  
35 mM (NH4)2SO4 
5% Glycerol  
5 mM DTT 
(Appleby et al., 
2005) 
136 Infectious bursal 
disease virus 
RdRp VP1 2PGG 2.50 P6122 Hanging drop (20°C) 0.1 M HEPES, pH 7.5 
1.3 M Na malonate 
 
(Pan et al., 2007) 




























10 mM NaI 
137 Infectious bursal 
disease virus 
VP1 pol with 
oligopeptide 
2QJ1 3.48 P6122 Hanging drop (20°C) 10-12% PEG 3350 
0.3-0.5 M LiNO3, pH 6.5-8.0 
(Garriga et al., 2007) 
138 Infectious bursal 
disease virus 
RdRp 2PUS 2.40 P6122 Hanging drop (25°C) 
139 Infectious bursal 
disease virus 
VP1 pol with 
oligopeptide 
2R70 2.70 P6122 Hanging drop (20°C) 5% PEG 3350  
0.4 M LiNO3  
0.1 M Tris, pH 7.3 
140 Infectious bursal 
disease virus 
VP1 pol with 
Mg2+ ion 
2R72 3.15 P6122 Hanging drop (20°C) 10% PEG 3350  
0.4 M LiNO3  






3ZED 2.20 P21212 20% (w/v) PEG 3350 
0.2 M KF, pH 7.5 







2YI8 2.30 P212121 Sitting drop 18-20% PEG 3350  
0.09-0.1 M Bis-Tris Propane 
pH 7.5 
0.18-0.2 M Na Citrate 








2YI9 2.20 P212121 Sitting drop 
144 Infectious RNA 2YIA 3.02 P212121 Sitting drop 







































2YIB 3.80 P212121 Sitting drop 20% PEG 3350  
0.1 M Bis-Tris propane, pH 7.5  
0.2 M Na Citrate  
20 mM ATP  
5% MPD  
10 mM NaOH 
146 Influenza C virus RdRp 5D9A 4.30 P212121 Sitting drop (20°C) 0.2 M NaCl  
25% PEG 4000 
0.1 M HEPES, pH 7.5 
(Hengrung et al., 
2015) 
147 Influenza C virus RdRp 5D98 3.90 P43212 Sitting drop (20°C) Morpheus condition G2: 
10% PEG 8000, 
20% ethylene glycol  
0.02 M carboxylic acids  
0.1 M MES/imidazole 
148 Japanese 
Encephalitis virus 
RdRp 4MTP 3.65 P212121 Hanging drop (25°C) 10-15% PEG 5000 MME  
0.1 M Tris-HCl, pH 8.0 
0.2 M NaSCN 
 
(Surana et al., 2014) 





























149 Murine Norovirus RdRp 3NAH 2.75 C2 Hanging drop 1 M (NH4)2SO4 
0.1 M Cacodylate pH 6.5 
To Be Published 
150 Murine Norovirus RdRp 3NAI 2.55 C2 Hanging drop (4°C) 
151 Norwalk Virus Polymerase 
(Triclinic) 
1SH0 2.17 P1 Hanging drop (22°C) 24% PEG 8000  
0.1-0.2  M (NH4)2SO4  
50 mM Tris-HCl, pH 7.5  
15 % Glycerol  
14 mM 2-mercaptoethanol 
 
(Ng et al., 2004) 




1SH2 2.30 C2221 Hanging drop (22°C) 
153 Norwalk Virus Polymerase 
(MgSO4 
crystal form) 
1SH3 2.95 P212121 Hanging drop (22°C) 
154 Murine Norovirus RdRp 3MWV 2.20 P212121  (11°C) 0.1 M MES, pH 5.4  
21% PEG 5000 MME  
0.4 M (NH4)2SO4  
10% Glycerol 
(LaPlante et al., 
2010) 
155 Murine Norovirus RdRp 3QID 2.50 C2 Hanging drop (22°C) 1.26 M (NH4)2SO4 
0.1 M Cacodylate pH 6.5 
(Lee et al., 2011) 
156 Murine Norovirus RdRp with 2 
thiouridine 
(2TU) 
3SFG 2.20 C2 Hanging drop (4°C) 2 M (NH4)2SO4  
Cacodylate pH 6.5  
0.2 M NaCl 
(Alam et al., 2012) 




























157 Murine Norovirus RdRp with 
ribavirin 
3SFU 2.50 C2 Hanging drop (20°C) 1.26 M (NH4)2SO4  
CHES, pH 9.5  
0.2 M NaCl 
158 Murine Norovirus Polymerase 
bound to 
NF023 
3UPF 2.60 C2 Hanging drop (20°C) 1.5 M (NH4)2SO4,  
11% Glycerol 
50 mM Tris pH 8.4 
159 Murine Norovirus Polymerase 
with Suramin 
3UR0 2.45 C2 Hanging drop (20°C) 1.3 M (NH4)2SO4  
10% Glycerol  
0.1 M Tris, pH 8.4 
160 Murine Norovirus Polymerase 
with a suramin 
derivative 
4NRU 2.30 P 21 Microbatch 1.6 M (NH4)2SO4  
12% Glycerol 
0.1 M Tris-HCl pH 8.4 
(Croci, Pezzullo, et 
al., 2014) 
161 Murine Norovirus RdRp in 
complex with 
PPNDS 
4O4R 2.40 C2 Macrobatch (20°C) 1.6 M (NH4)2SO4  
12% Glycerol 
0.1 M Tris-HCl pH 8.4 
(Croci, Tarantino, et 
al., 2014) 
162 Poliovirus Polymerase 
full length apo 
1RA6 2.00 P65 Hanging drop (16°C) 1.5 M Na Acetate, 0.1 M 
Cacodylic acid, pH 7.1 
2 mM DTT 
(Thompson & 
Peersen, 2004) 
163 Poliovirus Polymerase 
with GTP 
1RA7 2.35 P65 Hanging drop (16°C) 

































1RAJ 2.50 P3121 Hanging drop (16°C) 1.5 M Ammonium Formate,  
0.1 M NaCl, 0.05 M HEPES, 
pH 7.0, 2 mM DTT 
165 Poliovirus 3D 
polymerase 
1RDR 2.40 P3121 Hanging drop (16°C)  
166 Poliovirus Polymerase 
G1A mutant 
1TQL 2.30 P65 Hanging drop (16°C) 2M Na-Acetate, 2 mM DTT  
0.1 M Cacodylic acid, pH 7.1 
167 Poliovirus RdRp 3Dpol 
G64S mutant 
2IJF 3.00 P65 Hanging drop (20°C) 2 M NaOAc 
0.1 M HEPES, pH 7.0 
(Marcotte et al., 
2007) 
168 Poliovirus Polymerase 
with ATP and 
Mg2+ 
2ILY 2.60 P65 Hanging drop (16°C) 2 M Na Acetate 
0.1 M Cacodylic acid, pH 7.1 
2 mM DTT 
 
(Thompson et al., 
2007) 
169 Poliovirus Polymerase 
with GTP and 
Mn2+ 
2ILZ 2.50 P65 Hanging drop (16°C) 
170 Poliovirus Polymerase 
with CTP and 
Mn2+ 
2IM0 2.25 P65 Hanging drop (16°C) 
171 Poliovirus Polymerase 
with CTP and 
Mn2+ 
2IM1 2.50 P65 Hanging drop (16°C) 





























172 Poliovirus Polymerase 
with UTP and 
Mn2+ 
2IM2 2.35 P65 Hanging drop (16°C) 
173 Poliovirus Polymerase 
with UTP and 
Mn2+ 
2IM3 2.60 P65 Hanging drop (16°C) 





2.20 P65 Hanging drop (16°C) 0.25 M Na Acetate  
0.1 M Cacodylic acid, pH 7.0  
2 mM DTT, 30% PEG 400 
 
(Sholders & Peersen, 
2014) 
175 Poliovirus Polymerase 
C290V loop 
mutant 
4NLP 2.20 P65 Hanging drop (16°C) 
176 Poliovirus Polymerase 
C290F loop 
mutant 
4NLQ 2.30 P65 Hanging drop (16°C) 
177 Poliovirus Polymerase 
C290S loop 
mutant 
4NLR 1.85 P65 Hanging drop (16°C) 
178 Poliovirus Polymerase 
S288A loop 
mutant 
4NLS 2.00 P65 Hanging drop (16°C) 
179 Poliovirus Polymerase 
S291P loop 
4NLT 2.50 P65 Hanging drop (16°C) 





























180 Poliovirus Polymerase 
G289A loop 
mutant 
4NLU 1.96 P65 Hanging drop (16°C) 
181 Poliovirus Polymerase 
G289A/C290F 
loop mutant 
4NLV 2.30 P65 Hanging drop (16°C) 
182 Poliovirus Polymerase 
G289A/C290I 
loop mutant 
4NLW 2.10 P65 Hanging drop (16°C) 
183 Poliovirus Polymerase 
G289A/C290
V loop mutant 
4NLX 2.60 P65 Hanging drop (16°C) 
184 Poliovirus Polymerase 
C290E loop 
mutant 
4NLY 2.30 P65 Hanging drop (16°C) 
185 Poliovirus RdRp low-
fidelity mutant 
3D pol H273R 
4R0E 3.00 P65  (20°C) 2 M Na Acetate 
0.1 M Na Cacodylate, pH 6.8 




RdRp 1HHS 2.00 P21 10% PEG 8000 
0.1 M MES 
2 mM MnCl2 
(Butcher et al., 
2001) 































RdRp 2JLF 3.20 P32  15-20% PEG 4000  
8.5% Isopropanol  
15% Glycerol  
0.1 M HEPES, pH 7.5 




RdRp 4A8F 3.30 P21  20% PEG 4000 
0.1 M HEPES, pH 7.5 
8.5% Isopropanol 
15% Glycerol  
2 mM MnCl2 
 
(Wright et al., 2012) 
189 Pseudomonas 
phage Phi6 
RdRp 4A8K 2.90 P21  
190 Pseudomonas 
phage Phi6 
RdRp 4A8M 2.90 P21  
191 Pseudomonas 
phage Phi6 
RdRp 4A8O 2.67 P21  
192 Pseudomonas 
phage Phi6 
RdRp 4A8Q 3.00 P21  20% PEG 2000 
0.1 M MES, pH 6.5 
193 Pseudomonas 
phage Phi6 
RdRp 4A8S 2.90 P21  
194 Pseudomonas 
phage Phi6 






1KHV 2.50 P212121 Hanging drop (25°C) 10–12% PEG 8000 
 0.1 M Tris-HCl, pH 7.5  
(Ng et al., 2002) 




























Disease Virus 0.2 M Na thiocyanate  
0.1 M L-proline  
15% Glycerol  
7% 1,6-hexanediol,  
0.1% CHAPS,  
5 mM CaCl2  






1KHW 2.70 P212121 Hanging drop (25°C) 10-12% PEG 8000  
0.1 M Tris, pH 7.5 
0.2 M sodium thiocyanate 
0.1 M L-proline  
15% (w/v) glycerol  
7% (v/v) 1,6-hexanediol  
0.1% (w/v) CHAPS  
5 mM CaCl2,  
2 mM MgCl2  
197 Thielavia terres RdRp QDE-1 5FSW 3.19 P21 0.1 M Tris, pH 8.0 
75 mM NaCl  
10% PEG 10000 
(Qian et al., 2016) 





































P212121 Sitting drop (20°C) 12% PEG 8000 
0.75 M Li2SO4 
(Ferrero et al., 2015) 








3.50 I222 Sitting drop (20°C) 





4XHA 3.00 C2221 Sitting drop (20°C) 
201 Thosea asigna 
virus 





































Table S2 The calculated volume for each stock solution used in the distinct conditions of the screen is provided (Total volume: 10 ml). 
1 2 3 4 5 6 7 8 9 10 11 12 
A 0.5 ml MES, pH 5.0 
7.3 ml NaCl 
1.5 ml Glycerol 
0.7 ml H2O 
0.5 ml MMT, pH 5.5 
7.3 ml NaCl 
1.5 ml Glycerol 
0.7 ml H2O 
0.5 ml (CH3)2AsO2Na, 
pH 6.5  
7.3 ml NaCl 
1.5 ml Glycerol 
0.7 ml H2O 
0.85 ml HEPES, pH 7.0 
7.3 ml NaCl 
1.5 ml Glycerol 
0.35 ml H2O 
0.85 ml Tris, pH 7.5 
3.18 ml (NH4)2SO4 
2.5 ml Glycerol 
3.46 ml H2O 
0.5 ml Tris, pH 7.5 
3.22 ml (NH4)2SO4 
2.45 ml Glycerol 
3.83 ml H2O 
0.5 ml Tris, pH 8.0 
3.22 ml (NH4)2SO4 
2.45 ml Glycerol 
3.83 ml H2O 
0.5 ml Tris, pH 8.5 
3.22 ml (NH4)2SO4 
2.45 ml Glycerol 
3.83 ml H2O 
0.5 ml SPG, pH 9.0 
3.22 ml (NH4)2SO4 
2.45 ml Glycerol 
3.83 ml H2O 
1 ml MES, pH 5.0 
0.02 ml MnCl2
0.02 ml MgCl2
3.25 ml (NH4)2SO4 
5.71 ml H2O 
1 ml Bis-Tris, pH 6.1 
0.01 ml DTT 
0.2 ml NiSO4 
30.25 ml (NH4)2SO4 
5.54 ml H2O 
1 ml 
(CH3)2AsO2Na, pH 6.5  
2.5 ml (NH4)2SO4 
6.5 ml H2O 
B 1 ml 
(CH3)2AsO2Na, pH 6.5 
0.4 ml NaCl 
5 ml (NH4)2SO4 
3.6 ml H2O 
0.5 ml HEPES, pH 7.0 
0.2 ml NaCl 
3.75 ml (NH4)2SO4 
0.02 ml DTT 
5.53 ml H2O 
0.5 ml HEPES, pH 7.5 
0.2 ml NaCl 
3.75 ml (NH4)2SO4 
0.02 ml DTT 
5.53 ml H2O 
0.5 ml Tris, pH 8.0 
3.75 ml (NH4)2SO4 
10.1 ml Glycerol 
4.65 ml H2O 
0.5 ml Tris, pH 8.5 
3.75 ml (NH4)2SO4 
10.1 ml Glycerol 
4.65 ml H2O 
2 ml CHES, pH 9.5 
0.4 ml NaCl 
30.15 ml (NH4)2SO4
4.45 ml H2O 
2 ml CAPS, pH 10.0 
1 ml Li2SO4 
5ml (NH4)2SO4
2 ml H2O 
1 ml MMT, pH 5.0 
5.333 ml K/Na Tartrate 
3.667 ml H2O 
1 ml MMT, pH 5.5 
5.333 ml K/Na Tartrate 
0.05 ml of PEG 550 
MME 
3.617 ml H2O 
1 ml MMT, pH 6 
5.333 ml K/Na Tartrate 
3.667 ml H2O 
1 ml 
(CH3)2AsO2Na, pH 6.5 
5.333 ml K/Na Tartrate 
3.667 ml H2O 
1 ml HEPES, pH 7.0 
5.333 ml K/Na Tartrate 
0.1 ml of PEG 400 
3.567 ml H2O 
C 1 ml HEPES, pH 7.5 
5.333 ml K/Na Tartrate 
3.667 ml H2O 
1 ml Tris-HCl, pH 8.5 
5.333 ml K/Na Tartrate 
0.1 ml PEG 5000 MME 
3.567 ml H2O 
1 ml Tris-HCl, pH 8.5 
5.333 ml K/Na Tartrate 
0.2 ml PEG 2000 MME 
3.467 ml H2O 
1 ml 
(CH3)2AsO2Na, pH 6.5 
0.25 ml NaCl 
4 ml Na3C6H5O7
4.75 ml H2O 
1 ml HEPES, pH 7.5 
0.1 ml NaI 
3.823 ml C3H2O4Na2
5.077 ml H2O 
1 ml HEPES, pH 7.0 
6.67 ml C2H3NaO2
0.1 ml PEG 550 MME 
20.233 ml H2O 
1 ml (CH3)2AsO2Na, 
pH 7.1 
6.67 ml C2H3NaO2
2.33 ml H2O 
0.5 ml MES, pH 5.0 
2 ml NaCl 
2 ml PEG 400 
0.05 ml DTT 
5.45 ml H2O 
1 ml Bis-Tris propane, 
pH 6.5 
00.125 ml (NH4)2SO4 
3 ml PEG 550 MME 
5.875 ml H2O 
1 ml HEPES, pH 7.5 
0.5 ml MgCl2 
3 ml PEG 550 MME 
5.5 ml H2O 
1 ml HEPES, pH 7.5 
0.5 ml MnCl2 
3 ml PEG 550 MME 
5.5 ml H2O 
0.5 ml Tris, pH 7.5 
0.2 ml NH4OAc 
2.5 ml PEG 550 MME 
6.8 ml H2O  
D 1 ml Tris, pH 8.0 
2.5 ml PEG 550 MME 
6.5 ml H2O 
1 ml Tris, pH 8.0 
2 ml PEG 550 MME 
7 ml H2O 
1 ml Tris, pH 8.5 
2 ml PEG 550 MME 
7 ml H2O 
1 ml Bicine, pH 9.0 
2.5 ml PEG 550 MME 
6.5 ml H2O 
0.5 ml MES, pH 6.5 
0.5 ml (NH4)2SO4 
0.25 ml NH4OAc 
2.5 ml PEG 1000 
60.25 ml dH2O 
1 ml MES, pH 8.0 
2.5 ml PEG 1500 
6.5 ml H2O 
1 ml MES, pH 6.5 
5 ml PEG 2000 
4 ml H2O 
00.1 ml NH4OAc, pH 
5.0 
0.5 ml (NH4)2SO4 
6 ml PEG 2000 MME 
3.4 ml dH2O 
1 ml HEPES, pH 7.0 
8.333 ml C4H6O4 
00.1 ml PEG 2000 
MME 
0.567 ml H2O 
1 ml Na3C6H5O7, pH 
5.5 
3.6 ml PEG 3350 
1.4 ml Glycerol 
4 ml H2O 
1 ml Bis-Tris propane, 
pH 6.0 
0.5 ml NH4OAc 
6 ml PEG 3350 
2.5 ml H2O 
1 ml MES, pH 6.0 
4 ml LiNO3 
2 ml PEG 3350 
3 ml H2O 
E 1 ml Bis-Tris Propane, 
pH 7.5 
2 ml Na3C6H5O7 
4 ml PEG 3350 
3 ml H2O 
1 ml Bis-Tris Propane, 
pH 7.5 
1 ml Na3C6H5O7 
4 ml PEG 3350 
0.5 ml MPD 
0.05 ml MnCl2 
0.033 ml ATP 
0.02 ml NaOH 
3.397 ml H2O 
1 ml MMT Buffer pH 
8.0 
3.5 ml LiNO3 
2.4 ml PEG 3350 
30.1 ml H2O 
0.333 ml C2H3NaO2, pH 
4.7 
0.125 ml (NH4)2SO4 
4 ml PEG 4000 
0.05 ml DTT 
5.492 ml H2O 
0.5 ml Na3C6H5O7, pH 
4.9 
50.2 ml PEG 4000 
0.75 ml Glycerol 
3.550 ml H2O 
0.5 ml MES, pH 5.0 
0.05 ml DTT 
4 ml PEG 4000 
1 ml Glycerol 
4.45 ml H2O 
0.5 ml MES, pH 5.0 
4 ml PEG 4000, 0.5 ml 
Glycerol 
5 ml H2O 
1 ml Na3C6H5O7, pH 
5.0 
4 ml PEG 4000 
0.05 ml DTT 
1 ml Glycerol 
3.950 ml H2O 
0.333 ml C2H3NaO2, 
pH 5.0 
0.6 ml NaCl 
3.6 ml PEG 4000 
0.004 ml β-
mercaptoethanol 
5.463 ml H2O 
0.333 ml C2H3NaO2, pH 
5.0 
0.6 ml NaCl 
30.2 ml PEG 4000 
1 ml Glycerol 
0.004 ml β-
mercaptoethanol 
4.863 ml H2O 
0.5 ml Na3C6H5O7, pH 
5.6 
0.2 ml NH4OAc 
6.6 ml PEG 4000 
0.4 ml γ-butyrolactone 
2.3 ml H2O 
1 ml Na3C6H5O7, pH 
5.6 
0.087 ml (NH4)2SO4 
8 ml PEG 4000 
0.5 ml Glycerol 
0.05 ml DTT 
0.363 ml H2O 
F 1 ml MES, pH 6.0 
2 ml Mg(CH3COO)2 
6 ml PEG 4000 0.4 ml 
γ- butyrolactone 
0.6 ml H2O 
0.333 ml C2H3NaO2, pH 
6.0 
0.6 ml NaCl 
2.8 ml PEG 4000 
0.004 ml β-
mercaptoehanol 
60.263 ml dH2O 
0.5 ml Na3C6H5O7, pH 
6.5 
3.4 ml PEG 4000 
60.1 ml H2O 
0.333 ml C2H3NaO2, pH 
6.5 
0.350 ml NH4OAc 
5 ml PEG 4000 
4.317 ml H2O 
1 ml (CH3)2AsO2Na, 
pH 6.5 
2 ml Mg(CH3COO)2 
6 ml PEG 4000 
1 ml H2O 
0.5 ml Na3C6H5O7, pH 
6.8 
0.8 ml PEG 4000 
0.7 ml Isopropanol 
8 ml H2O 
0.5 ml Tris, pH 7.5 
50.2 ml PEG 4000 
0.75 ml Glycerol 
3.55 ml H2O 
1 ml Na-HEPES, pH 
7.5 
00.1 ml CaCl2 
0.4 ml NaCl 
5 ml PEG 4000 
1 ml Glycerol 
2.5 ml H2O 
1 ml HEPES, pH 7.5 
4 ml PEG 4000 
0.85 ml Isopropanol 
1.5 ml Glycerol 
2.65 ml H2O 
1 ml HEPES, pH 7.5 
0.02 ml MnCl2
4 ml PEG 4000 
0.85 ml Isopropanol 
1.5 ml Glycerol 
2.63 ml H2O 
1 ml Tris, pH 8.0 
0.02 ml MnCl2 
4 ml PEG 4000 
0.85 ml Isopropanol 
1.5 ml Glycerol 
2.63 ml H2O 
1 ml Tris, pH 8.0 
0.02 ml MnCl2 
4 ml PEG 4000 
0.85 ml Isopropanol 
1.5 ml Glycerol 
2.63 ml H2O 
G 1 ml Bicine, pH 9.0 
0.02 ml MnCl2 
4 ml PEG 4000 
0.85 ml Isopropanol 
1.5 ml Glycerol 
2.63 ml H2O 
3.75 ml Li2SO4 
2.4 ml PEG 8000 
3.85 ml H2O 
0.333 ml C2H3NaO2, 
pH 5.0 
0.5 ml (NH4)2SO4 
5.4 ml PEG 5000 MME 
3.767 ml H2O 
1 ml MES, pH 5 
1 ml (NH4)2SO4 
40.2 ml PEG 5000 
MME 
1 ml Glycerol 
2.8 ml dH2O 
0.5 ml Na3C6H5O7, pH 
5.5 
1.6 ml PEG 8000 
0.5 ml Isopropanol 
7.4 ml H2O 
1 ml MES, pH 6.0 
00.1 ml MnCl2 
2.8 ml PEG 8000 
1.4 ml Isopropanol 
0.05 ml TCEP 
4.65 ml H2O 
1 ml (CH3)2AsO2Na, 
pH 6.4 
2 ml Mg(CH3COO)2 
3 ml PEG 8000 
4 ml H2O 
1 ml MES, pH 6.5 
0.5 ml (NH4)2SO4 
5 ml PEG 5000 MME 
3.5 ml H2O 
1 ml M Na3C6H5O7, pH 
6.5 
1 ml PEG 8000, 0.5 ml 
Isopropanol 
7.5 ml H2O 
1 ml Buffer System 1, 
pH 6.5 (Morpheus) 
0.2 ml C4H6O5 
2 ml PEG 8000 
2 ml Ethylene Glycol 
4.8 ml H2O 
1 ml MES, pH 6.5 
0.02 ml M MnCl2
2 ml PEG 8000 
6.98 ml H2O 
1 ml HEPES pH 7.5 
2 ml PEG 8000  
0.8 ml Ethylene Glycol 
60.2 ml H2O 
H 1 ml Tris, pH 7.5 
0.01 ml Tween-20 
0.05 ml CaCl2 
0.02 ml MgCl2 
2.4 ml PEG 8000 
1.5 ml Glycerol 
1.4 ml 1,6-hexanediol 
0.5 ml Tris, pH 7.5 
0.5 ml (NH4)2SO4 
4.8 ml PEG 8000 
1.5 ml Glycerol 
2.7 mldH2O 
0.5 ml Tris, pH 7.5 
0.25 ml (NH4)2SO4 
0.2 ml MgSO4
4.8 ml PEG 8000 
1.5 ml Glycerol 
2.75 ml H2O 
0.5 ml Tris, pH 8.0 
0.5 ml (NH4)2SO4 
4.8 ml PEG 8000 
1.5 ml Glycerol 
2.7 ml H2O 
0.5 ml Tris, pH 8.5 
0.5 ml (NH4)2SO4 
4.8 ml PEG 8000 
1.5 ml Glycerol 
2.7 ml H2O 
1 ml Tris, pH 7.5 
0.15 ml NaCl 
2 ml PEG 10000 
6.85 ml H2O 
1 ml Tris, pH 8.0 
0.15 ml NaCl 
2 ml PEG 10000 
6.85 ml H2O 
1 ml Tris, pH 8.5 
0.15 ml NaCl 
2 ml PEG 10000 
6.85 ml H2O 
2 ml NaH2PO4, pH 7.0 
1.4 ml PEG 20000 
6.6 ml H2O 
2 ml HEPES, pH 7.5 
1.4 ml PEG 20000 
6.6 ml H2O 
2 ml Tris, pH 8.0 
1.4 ml PEG 20000 
6.6 ml H2O 
2 ml HEPES, pH 8.5 
1.4 ml PEG 20000 
6.6 ml H2O 




























Table S3 List of chemicals used in the preparation of the crystallization screen. The table provides 
the names, source of the chemicals and their catalogue numbers and stock solutions.   
Reagent Company Catalogue No. Stock solution 
1,6-Hexanediol Sigma 240117 50% (v/v) 
Ammonium Acetate Acros Organics /Fisher AC401152500 1 M 
Ammonium Sulfate Sigma A4418 4 M 
ATP Acros Organics /Fisher AC102800100 6 M 
Bicine Bio Basic Inc. BB0266 1 M 
Bis-Tris Propane Melford B7510 1 M 
Buffer System 1 - Morpheus Molecular Dimension MD2-100-100 100% (v/v) 
γ-Butyrolactone Aldrich B103608 100% (w/v) 
Calcium Chloride Sigma-Aldrich C3306 1 M 
CHAPS Melford B2006 0.5 M 
CHES Bio Basic Inc. CB0115 0.5 M 
DTT Fluka 43817 1 M 
Ethylene Glycol Alfa Aesar A11591 100% (w/v) 
Glycerol Melford G1345 100% (w/v) 
HEPES Melford B2001 1 M 
Isopropanol Fisher Scientific BP2618 100% (v/v) 
Lithium Nitrate Sigma-Aldrich 227986 1 M 
Lithium Sulfate Acros Organics /Fisher 218331000 2 M 
L-Proline Melford P0717 100 mM 
Magnesium Acetate Sigma-Aldrich 2286448 1 M 
Magnesium Chloride Melford M0533 1 M 
Malic Acid Acros Organics /Fisher 125252500 1 M 
Manganese Chloride Alfa Aesar 11868 1 M 
MES Sigma-Aldrich M2933 1 M 
MPD Sigma-Aldrich 112100 100% (w/v) 
Nickel Sulfate Fisher Scientific 10568810 1 M 























PEG 400 Sigma-Aldrich 202398 100% (w/v) 
PEG 1000 Acros Organics /Fisher AC192250010 50% (w/v) 
PEG 1500 Fluka 81210 50% (w/v) 
PEG 2000 VWR 200007-386 50% (w/v) 
PEG 3350 Sigma-Aldrich 202444 50% (w/v) 
PEG 4000 Sigma-Aldrich 95904 50% (w/v) 
PEG 8000 Sigma-Aldrich 89510 50% (w/v) 
PEG 10000 Sigma-Aldrich 81280 50% (w/v) 
PEG 20000 Sigma-Aldrich 95172 30% (w/v) 
PEG 550 MME Aldrich 202487 100% (w/v) 
PEG 2000 MME VWR AAA17925-30 30% (w/v) 
PEG 5000 MME Sigma-Aldrich 81323 50% (w/v) 
Sodium Acetate Sigma-Aldrich 52889 3 M 
Sodium Cacodylate Sigma-Aldrich C4945 1 M 
Sodium Chloride Sigma-Aldrich S3014 5 M 
Sodium Citrate Alfa Aesar L12557 1 M 
Sodium Dihydrogen Phosphate Melford S2318 1 M 
Sodium Hydroxide Sigma-Aldrich 221465 5 M 
Sodium Iodide Millipore Merck 106523 2 M 
Sodium Malonate Sigma-Aldrich 63409 3.4 M 
Sodium Potassium Tartrate Sigma-Aldrich 217255 2 M 
Succinic Acid Acros Organics /Fisher AC158742500 2 M 
TCEP Melford T2650 1 M 
Tris Melford B2005 1 M 
Tri-Sodium Citrate Acros Organics /Fisher 227130010 1 M 
Tween-20 Millipore Merck 655204 100% (w/v) 
β-Mercaptoethanol Acros Organics /Fisher 125472500 14.3 M 























Table S4 Summary of approximate diffraction limits obtained for Dengue RdRp3 crystals in various well conditions of the crystallization screen. 
Well Number Resolution Well Number Resolution 
A3 No diffraction D6 10.0 
A4 No diffraction D7 3.0 
A6 10.0 D11 12.0 
A11 10.0 E1 7.0 
A12 8.0 E2 4.5 
B4 3.0 E4 2.9 
B5 15.0 E6 20.0 
B6 No diffraction E8 4.0 
B9 2.3 E12 5.0 
B11 15.0 F1 15.0 
B12 3.1 F2 12.0 
C2 2.3 F3 17.0 
C3 2.7 F9 14.0 
C6 2.2 G1 2.3 
D1 2.1 G2 2.3 
D2 2.0 G4 6.0 
D3 15.0 G8 8.0 
D5 2.7 H4 No diffraction 




























Table S5 Data collection and structure refinement statistics of dengue RdRp3 structures obtained from different crystallization conditions in the RdRp 
Screen.  







58.1, 90, 90, 
90 
162.1, 180.0, 
57.9, 90, 90, 
90 
160.8, 177.9, 
57.9, 90, 90, 
90 
162.5, 179.6, 
58.1, 90, 90, 
90 
161.4, 178.3, 
58.0, 90, 90, 
90 
162.4, 180.0, 
58.3, 90, 90, 
90 
161.5, 179.0, 
58.0, 90, 90, 
90 
163.5, 180.6, 
58.3, 90, 90, 
90 
163.8, 181.0, 
58.3, 90, 90, 
90 
162.7, 179.7, 
58.1, 90, 90, 
90 
162.8, 179.4, 
58.1, 90, 90, 
90 
162.1, 179.5, 
58.1, 90, 90, 
90 
Space group P21 C2221 C2221 C2221 C2221 C2221 C2221 C2221 C2221 C2221 C2221 C2221 C2221 
Resolution range 48.6 – 3.0 60.5 – 2.3 48.7 – 3.0 80.4 – 2.3 48.8 – 2.7 48.6 – 2.2 60.3 – 2.1 48.7 – 2.0 49.0 – 2.7 81.9 – 3.0 60.3 – 2.9 48.8 – 2.3 81.1 – 2.3 




72867 (9527) 166100 
(25269) 








58720 (7835) 76136 (9760) 168413 
(25106) 
690005 (7092) 
Unique reflections 33463 (4841) 38149 (5508) 15767 (2268) 37243 (5371) 23467 (3404) 42774 (6205) 49636 (7190) 55928 (8180) 25451 (3633) 17272 (2491) 19297 (2775) 37242 (5486) 36741 (3712) 
Completeness (%) 99.4 (99.7) 98.9 (99.1) 99.6 (99.6) 99.7 (99.9) 98.8 (99.7) 99.5 (99.7) 99.0 (99.6) 98.1 (99.6) 99.5 (99.6) 97.3 (98.0) 99.7 (99.7) 99.2 (97.6) 96.2 (98.6) 
Multiplicity 3.0 (3.0) 3.8 (4.0) 4.6 (4.2) 4.5 (4.7) 3.7 (3.8) 5.7 (5.4) 3.4 (3.3) 4.4 (4.6) 5.8 (6.0) 3.4 (3.1) 3.9 (3.5) 4.5 (4.6) 11.0 (3.0) 
R merge (%) 13.9 (44.0) 8.6 (50.4) 15.5 (58.8) 10.0 (38.8) 13.6 (50.4) 7.7 (70.2) 8.4 (42.0) 9.8 (72.0) 10.2 (60.3) 14.4 (58.5) 10.8 (15.8) 6.6 (50.1) 4.7 (26.9) 
I/∑I 6.8 (2.4) 10.9 (3.2) 8.2 (2.0) 9.3 (3.1) 10.6 (4.3) 15.1 (2.4) 8.5 (2.4) 9.8 (2.0) 14.4 (3.3) 6.4 (1.9) 9.4 (5.2) 13.9 (2.8) 14.5 (4.5) 
R work/R free (%) 17.5/25.2 18.4/24.4 18.3/26.1 20.8/26.2 17.4/24.3 20.0/23.4 20.2/26.4 24.6/27.0 17.7/22.9 18.6/26.5 21.6/28.4 17.7/22.5 17.6/22.4 
Wilson B (2) 54.1 33.0 58.4 28.1 27.8 28.7 25.9 24.3 28.6 52.6 33.2 41.0 33.3 
r.m.s.d. bond 
length 
0.018 0.013 0.016 0.013 0.013 0.012 0.012 0.013 0.013 0.017 0.014 0.012 0.012 
r.m.s.d. bond 
angles 
1.706 1.213 1.704 1.298 1.295 1.140 1.152 1.331 1.215 1.742 1.588 1.177 1.240 
Ramachandran  
Favoured 90.0 96.0 97.0 95.3 94.7 96.2 96.7 96.7 96.7 88.1 96.6 95.7 96.3 
Allowed 8.4 3.2 1.8 4.6 4.6 33 2.9 2.5 2.6 10.2 2.50 4.1 3.3 
Outliers 1.6 0.9 1.2 0.2 0.7 0.5 0.4 1.3 0.7 1.8 0.9 0.2 0.4 




























Table S6 Details of missing regions in the structures, PEG and water molecules in the structure of dengue RdRp3 solved from the screen. Interestingly, 
the flexible regions in motif G (~ 454 – 469) and motif F (~ 406 – 419) are missing in all the structures consistently proving all the structures are in the closed 
confirmation.   
Well Number on 
plate 
B4 B9 B12 C2 C3 C6 D1 D2 D5 D7 E4 G1 G2 
Resolution (Å) 3.0 2.3 3.0 2.3 2.7 2.2 2.1 2.0 2.7 3.0 2.9 2.3 2.3 
Missing regions Chain A 
311 – 317 
344 – 354 
406 – 418 
451 – 469 
583 – 586 
Chain B 
310 – 317 
344 – 356 
406 – 418 
453 – 469 
583 –588 
311 – 317 
406 – 417 
454 – 469 
312 – 315 
406 – 419 
454 – 469 
310 – 318 
343 – 353 
407 – 419 
454 – 469 
581 – 588 
311 – 317 
343 – 353 
407 – 419 
454 – 469 
581 – 588 
311 – 317 
344 – 349 
406 – 419 
454 – 469 
581 – 586 
311 – 318 
343 – 353 
406 – 419 
454 – 473 
581 – 588 
311 – 318 
344 – 348 
407 – 419 
454 – 469 
583 – 585 
406 – 419 
454 – 469 
311 – 317 
406 – 418 
454 – 469 
311 – 317 
406 – 418 
455 – 469 
314 – 316 
406 – 416 
456 – 469 
312 – 318 
405 – 418 
454 – 469 
No. of PEG 
molecules 
none 3 6 5 5 3 2 2 3 
 (1 –P6G) 
5 4 5 6 
No. of water 
molecules 
35 348 90 222 223 334 871 367 256 92 213 254 272 
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